Why Patients Are Switching to Wegovy in 2026
What Is Wegovy and Why Switch & Save Makes Sense
Understanding "Wegovy what is it" becomes crucial when you're considering switching GLP-1 medications. Wegovy contains semaglutide, the same active ingredient found in diabetes medication Ozempic, but it's specifically licensed by the MHRA for weight management. Unlike off-label prescribing, Wegovy is designed and approved for weight loss alongside a reduced-calorie diet and increased physical activity. This prescription-only medicine offers a legitimate switching option for patients currently using Mounjaro who want to explore alternatives.
The Switch & Save approach to Wegovy appeals to patients for several reasons beyond cost. Some experience different side effect profiles between GLP-1 medications, whilst others prefer Wegovy's longer room-temperature stability for travel or lifestyle convenience. Our clinical team at EverydayMeds regularly supports patients transitioning between these medications, ensuring continuity of care from the same trusted pharmacy. This eliminates the complexity of switching providers whilst changing treatments.
Wegovy Pricing Structure and Switch & Save Benefits
When exploring "Wegovy what is it" from a cost perspective, our pricing reflects genuine value for this prescription-only medicine. Starting doses begin at £79.99 for the 0.25mg pen, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to the maintenance dose of £209.99 (2.4mg). New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 to access these competitive prices. These rates often represent significant savings compared to other pharmacy providers.
Our bundle options provide convenience rather than just savings, particularly valuable for patients switching medications who want supply security. The Intro Trio (0.25mg, 0.5mg, and 1mg) costs £299.99, covering your first three months of dose escalation in one order. For patients on maintenance doses, our Ultimate Stability Trio provides three 2.4mg pens for £649.99, ensuring consistent supply without monthly reordering concerns. This approach particularly benefits patients switching from Mounjaro who want uninterrupted treatment progression.
Clinical Evidence Behind What Wegovy Is
Understanding "Wegovy what is it" requires examining the robust clinical evidence from the STEP trial programme. In the landmark STEP 1 trial, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP 2 trial demonstrated approximately clinically studied weight loss in patients with type 2 diabetes, whilst STEP 3 showed around clinically studied weight loss when combined with intensive behavioural therapy.
The recent SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events (hazard ratio 0.80), providing additional clinical rationale beyond weight management. For patients switching from other GLP-1 medications, this evidence base offers confidence in Wegovy's established efficacy profile. These results support clinical decision-making when prescribers help patients transition between different GLP-1 receptor agonists based on individual response and tolerance.
How Wegovy Works - Understanding the GLP-1 Mechanism
Answering "Wegovy what is it" mechanistically, this medication is a GLP-1 receptor agonist that mimics a natural hormone called glucagon-like peptide-1. This hormone normally signals fullness after eating, but many people with obesity have reduced sensitivity to these natural satiety signals. Wegovy binds to GLP-1 receptors in the brain's appetite control centres, particularly the hypothalamus, helping restore normal hunger and fullness responses. The medication may also slow gastric emptying, meaning food stays in the stomach longer, contributing to sustained feelings of satisfaction. Additionally, Wegovy can reduce food cravings and the reward response to high-calorie foods, addressing both physiological and psychological aspects of weight management alongside lifestyle modifications.
EverydayMeds Ordering Process for Wegovy Switches
Accessing Wegovy through our Switch & Save programme begins with a comprehensive 3-minute online clinical assessment, designed to capture your medical history, current medications, and treatment goals. Our prescribers review each application within 3 working days (or 24 hours with express service), ensuring appropriate dose selection whether you're switching from another GLP-1 medication or starting fresh. For patients transitioning from Mounjaro, our clinical team provides guidance on approximate dose equivalencies, though your prescriber makes the final determination based on your individual response and tolerance. Once approved, we dispatch your Wegovy via next-day delivery using specialized cold-chain packaging to maintain the required 2-8°C temperature throughout transit. This seamless process eliminates gaps in treatment when switching between GLP-1 medications.
Wegovy Storage and Practical Considerations
A key advantage when considering "Wegovy what is it" involves its superior storage flexibility compared to alternatives like Mounjaro. Wegovy pens must be stored in the fridge at 2-8°C before first use, but once removed, they remain stable at room temperature (below 30°C) for up to 6 weeks - significantly longer than Mounjaro's 21-day room temperature limit. This makes Wegovy particularly suitable for patients who travel frequently or prefer flexibility in storage arrangements. The FlexTouch pen device is pre-filled and disposable, requiring no mixing or assembly, with a fine 32-gauge needle that many patients find more comfortable than alternative injection systems. Dose escalation follows a mandatory schedule: 0.25mg for weeks 1-4, 0.5mg for weeks 5-8, 1mg for weeks 9-12, 1.7mg for weeks 13-16, and 2.4mg for week 17 onwards, ensuring gradual tolerance development. Patients cannot skip escalation steps, as this increases side effect risk and may compromise treatment effectiveness.
Switching Between GLP-1 Medications - What Wegovy Offers
Patients often ask "Wegovy what is it" when comparing switching options from their current GLP-1 treatment. Common reasons for switching include different side effect profiles, cost considerations, storage convenience, or availability issues with their current medication. Some patients find Wegovy's weekly injection schedule more manageable than alternatives, whilst others prefer its established cardiovascular benefits demonstrated in the SELECT trial. The transition typically involves a washout period or direct conversion, depending on your previous medication and current dose.
EverydayMeds uniquely positions patients for successful switches by stocking both Wegovy and Mounjaro, eliminating the need to change pharmacy providers when changing medications. Our clinical team understands the nuances of GLP-1 transitions, providing continuity of care and professional relationship throughout your weight management journey. This comprehensive approach ensures you receive consistent service quality whether continuing your current treatment or exploring Wegovy as an alternative option.
Start Your Wegovy Switch & Save Journey Today
Ready to discover what Wegovy is and whether switching makes sense for your situation? Our streamlined ordering process begins at https://everydaymeds.co.uk/collections/weight-loss, where you can complete your clinical assessment and explore our full range of dosing options. Remember to apply code FIRST40 if you're new to EverydayMeds, or DOSE25 for returning customers, to access our competitive pricing structure. Our GPhC-registered pharmacy (#9012878) ensures you receive authentic, properly stored medication with professional oversight throughout your treatment. With next-day delivery and comprehensive clinical support, switching to Wegovy has never been more straightforward or cost-effective. Take the first step towards understanding what Wegovy could offer your weight management goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
